

## Press Release

**Matthias Link**  
Corporate Communications

Fresenius SE  
Else-Kröner-Strasse 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2872  
F +49 6172 608-2294  
matthias.link@fresenius.com  
www.fresenius.com

November 4, 2010

### **Researchers and developers to present innovative projects during 11<sup>th</sup> Fresenius Inventors' Fair**

Promising innovations from a variety of medical specialties will be on display Nov. 17-19 during the 11<sup>th</sup> Fresenius Inventors' Fair in conjunction with the Medica international trade fair and congress in Dusseldorf, Germany. The event is the first time the ideas of 22 specially selected researchers, developers and inventors will be shown to a broad audience. The top three entries will be honored with the Fresenius Inventors' Award, which includes prize money totaling €10,000. The winning entries are picked on Medica's opening day by a jury comprised of medical specialists and industry representatives. About 40 doctors, scientists, engineers, technicians and health care professionals are among the entrants this year. The competition covers a broad spectrum of innovations – from a device for detecting contagious diseases in a person's breath to a mobile EKG (electrocardiograph) to submersible training equipment for knee and hip joints. The Fresenius Inventors' Fair is held every two years during the Medica event.

The competition's previous winner is a good example of just how innovative the ideas are at the Fresenius Inventors' Fair: Dr. Nicole Kikillus, an engineer from Karlsruhe, Germany, developed a particularly reliable method for detecting atrial fibrillation, even if no atrial fibrillation occurs during a medical checkup. This enables an early diagnosis and reduces the risk of stroke. The second-place finisher – a fluorescent method to identify and perform a sentinel node biopsy in cancer patients – already is being used in clinics. Other innovations from previous competitions include a special pen for diagnosing and treating neurological illnesses

such as Parkinson's disease, a needle that facilitates taking blood samples from newborns, an endoscope for nearly pain-free colonoscopies, a new procedure for manufacturing nitrate monoxide, and a mobile washing station for bedridden patients.

"Many promising medical inventions often go unnoticed, rather than benefitting as many patients as possible," said jury member Martin Hepper. "Fresenius wants to help researchers find companies to further develop or market their ideas. During the Inventor's Fair, they have the opportunity to present their innovations to a broad audience of specialists and industry contacts." As the experience of previous fair participants shows, many researchers have been successful in establishing instrumental liaisons with companies. Last year, Medica had more than 138,000 visitors from Germany and abroad.

*The Fresenius Inventors' Fair will be held Nov. 17-19 in Hall 8b during the Medica international trade fair and congress in Dusseldorf, Germany. The award ceremony will begin at 2 p.m. on Wednesday, Nov. 17. Medica runs Nov. 17-20, 2010, from 10 a.m. to 6:30 p.m. (Saturday until 5 p.m.). Additional information on the Inventors' Fair is available at [www.fresenius.de/erfindermesse](http://www.fresenius.de/erfindermesse), and about Medica at [www.medica.de](http://www.medica.de).*

# # #

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2009, Group sales were approximately €14.2 billion. On Sept. 30, 2010, the Fresenius Group had 136,458 employees worldwide.

For current information, visit the company's website at [www.fresenius.com](http://www.fresenius.com).

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Board of Management: Dr. Ulf M. Schneider (President and CEO), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götze, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler  
Supervisory Board: Dr. Gerd Krick (Chairman)  
Registered Office: Bad Homburg, Germany/Commercial Register No. HRB 10660